前列腺动脉栓塞治疗良性前列腺增生症状的结果:一个前性的单中心研究
Sina Delazar1, Sina Azadnajafabad1,2, Kavous Firouznia1
1Advanced Diagnostic and Interventional Radiology Research Center (ADIR), Imam Khomeini Hospital Tehran University of Medical Sciences Tehran Iran.
Health science reports
|March 13, 2025
概括
前列腺动脉栓塞 (PAE) 有效治疗良性前列腺增生症 (BPH),显著改善症状并减少前列腺体积,并发症率低. 这种微创手术为寻求缓解BPH的男性提供了安全的替代方案.
科学领域:
- 泌尿器科 泌尿器科 泌尿器科 泌尿器科
- 干预性放射学 干预性放射学
- 男人的健康 男人的健康
背景情况:
- 良性前列腺增生 (BPH) 是老年男性普遍存在的尿道疾病,其特征是下泌尿道症状.
- 前列腺动脉栓塞 (PAE) 已成为BPH的新型干预治疗选择.
- PAE对于耐药药物治疗患者或那些经历不良反应并且不是手术候选人的患者尤为重要.
研究的目的:
- 评估PAE在患有BPH的男性的临床疗效和安全性.
- 为了评估前列腺体积的变化和国际前列腺症状得分 (IPSS) 后的PAE.
- 确定PAE的临床成功率,复发率和并发症概况.
主要方法:
- 在2020年至2022年期间,对46名BPH男性进行PAE的前性单中心研究.
- 术前和术后的评估包括前列腺体积通过超声波和IPSS在3个月和12个月.
- 临床成功是由欧洲心血管和干预放射学会标准定义的;症状复发和并发症被记录下来.
主要成果:
- 观察到高临床成功率:PAE后3个月93%和12个月85%.
- 在IPSS (平均差异-16.2在3个月, -13.5在12个月) 和前列腺体积 (平均差异-36.0在3个月, -37.3在12个月) 显著减少.
- 在17.4%的病例中出现并发症 (5例勃起功能障碍,3例尿路感染);需要治疗或手术的症状复发发生在17.4%和15.2%的病例中.
结论:
- PAE在控制BPH症状和减少前列腺大小方面表现出显著的有效性.
- 这种手术的副作用率很低,并没有严重的并发症.
- 对于一些BPH患者来说,PAE是一种可行且安全的治疗选择.
相关概念视频
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
121
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
121
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
141
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
141